<code id='8C14B8857B'></code><style id='8C14B8857B'></style>

<acronym id='8C14B8857B'></acronym>

<center id='8C14B8857B'><center id='8C14B8857B'><tfoot id='8C14B8857B'></tfoot></center><abbr id='8C14B8857B'><dir id='8C14B8857B'><tfoot id='8C14B8857B'></tfoot><noframes id='8C14B8857B'>

<optgroup id='8C14B8857B'><strike id='8C14B8857B'><sup id='8C14B8857B'></sup></strike><code id='8C14B8857B'></code></optgroup>

<b id='8C14B8857B'><label id='8C14B8857B'><select id='8C14B8857B'><dt id='8C14B8857B'><span id='8C14B8857B'></span></dt></select></label></b><u id='8C14B8857B'></u>

~~<i id='8C14B8857B'><strike id='8C14B8857B'><tt id='8C14B8857B'><pre id='8C14B8857B'></pre></tt></strike></i>~~

explore

author entertainment

2025-10-02 01:30:03

Alexis Borisy — Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Male doctors called my cancer incurable. A female doctor showed it wasn't
Next article： Anesthesiologist group: stop taking Ozempic before surgery

Tags

Leave your comment

comprehensive

Study suggests new cause of Down syndrome: cells linked to aging

fashion

Novavax promises a turnaround & Lilly roils the obesity market

2025-10-02 01:21

JPM pitch from hospitals? Revenue streams outside of patient care

fashion

After affirmative action ruling, medical educators look to 'holistic review'

2025-10-02 00:00

Allen Institute goes after foundational questions, CEO Costa says

fashion

Dobbs anniversary: the lost opportunity of abortion as health care

2025-10-02 00:44